Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 plus rituximab for previously untreated follicular lymphoma
CTR20262076Phase 3Active
- Sponsor
- MSD
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CN201 and rituximab in follicular lymphoma (FL) (2 arms), sponsored by MSD. Started Jun 2026; status: active.
02
Drugs
CN201rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20262076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262076.